Compass Therapeutics unveils key secondary endpoint results from pivotal biliary tract cancer trial

April 27, 2026 07:30 AM EDTUpdated 04:44 PM R&D Up­dat­ed: Com­pass Ther­a­peu­tic­s' stock plum­mets as it un­veils more da­ta from piv­otal bil­iary tract can­cer tri­al Reynald Castaneda Deputy Editor A year af­ter it re­port­ed a Phase 2/3 suc­cess, Com­pass Ther­a­peu­tics on Mon­day re­vealed fur­ther re­sults for its close­ly watched bis­pe­cif­ic an­ti­body … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER